A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
Tarhini A, Lee S, Hodi F, Rao U, Cohen G, Hamid O, Hutchins L, Sosman J, Kluger H, Sondak V, Koon H, Lawrence D, Kendra K, Minor D, Lee C, Albertini M, Flaherty L, Petrella T, Kirkwood J. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. Journal Of Clinical Oncology 2017, 35: 9500-9500. DOI: 10.1200/jco.2017.35.15_suppl.9500.Peer-Reviewed Original ResearchHigh-dose interferon-alfaHigh-risk melanomaAdverse eventsAdjuvant therapyRFS analysisHigh-dose interferon alfa-2bThree-year RFS ratesTreatment related adverse eventsRelative safetyDiscontinuation of treatmentInterferon alfa-2bRelated adverse eventsCo-primary endpointsRegulatory approvalAdjuvant ipilimumabAdult ptsInoperable melanomaIpilimumab armInterferon alfaAlfa-2bRFS ratesPreliminary safetyDose levelsRecent approvalMelanoma